Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial - Lacour, J P; Paul, C; Jazayeri, S (J Eur Acad Dermatol Venereol, 2017)
et al.